Connection
Gregory Forlenza to Blood Glucose Self-Monitoring
This is a "connection" page, showing publications Gregory Forlenza has written about Blood Glucose Self-Monitoring.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
9.175 |
|
|
|
-
Messer LH, Berget C, Ernst A, Towers L, Slover RH, Forlenza GP. Initiating hybrid closed loop: A program evaluation of an educator-led Control-IQ follow-up at a large pediatric clinic. Pediatr Diabetes. 2021 06; 22(4):586-593.
Score: 0.480
-
Sopfe J, Vigers T, Pyle L, Giller RH, Forlenza GP. Safety and Accuracy of Factory-Calibrated Continuous Glucose Monitoring in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. Diabetes Technol Ther. 2020 10; 22(10):727-733.
Score: 0.448
-
Messer LH, Berget C, Forlenza GP. A Clinical Guide to Advanced Diabetes Devices and Closed-Loop Systems Using the CARES Paradigm. Diabetes Technol Ther. 2019 08; 21(8):462-469.
Score: 0.423
-
Forlenza GP, Buckingham BA, Christiansen MP, Wadwa RP, Peyser TA, Lee JB, O'Connor J, Dassau E, Huyett LM, Layne JE, Ly TT. Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2019 05; 21(5):265-272.
Score: 0.419
-
Forlenza GP, Ekhlaspour L, Breton M, Maahs DM, Wadwa RP, DeBoer M, Messer LH, Town M, Pinnata J, Kruse G, Buckingham BA, Cher?avvsky D. Successful At-Home Use of the Tandem Control-IQ Artificial Pancreas System in Young Children During a Randomized Controlled Trial. Diabetes Technol Ther. 2019 04; 21(4):159-169.
Score: 0.418
-
Forlenza GP, Kushner T, Messer LH, Wadwa RP, Sankaranarayanan S. Factory-Calibrated Continuous Glucose Monitoring: How and Why It Works, and the Dangers of Reuse Beyond Approved Duration of Wear. Diabetes Technol Ther. 2019 04; 21(4):222-229.
Score: 0.416
-
Forlenza GP, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, Ekhlaspour L, Church MM, Weinzimer SA, Jost E, Marcal T, Andre C, Carria L, Swanson V, Lum JW, Kollman C, Woodall W, Beck RW. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care. 2018 10; 41(10):2155-2161.
Score: 0.400
-
Messer LH, Berget C, Beatson C, Polsky S, Forlenza GP. Preserving Skin Integrity with Chronic Device Use in Diabetes. Diabetes Technol Ther. 2018 06; 20(S2):S254-S264.
Score: 0.395
-
Forlenza GP, Argento NB, Laffel LM. Practical Considerations on the Use of Continuous Glucose Monitoring in Pediatrics and Older Adults and Nonadjunctive Use. Diabetes Technol Ther. 2017 06; 19(S3):S13-S20.
Score: 0.369
-
Forlenza GP, Nathan BM, Moran A, Dunn TB, Beilman GJ, Pruett TL, Kovatchev BP, Bellin MD. Accuracy of Continuous Glucose Monitoring in Patients After Total Pancreatectomy with Islet Autotransplantation. Diabetes Technol Ther. 2016 08; 18(8):455-63.
Score: 0.342
-
Forlenza GP, Buckingham B, Maahs DM. Progress in Diabetes Technology: Developments in Insulin Pumps, Continuous Glucose Monitors, and Progress towards the Artificial Pancreas. J Pediatr. 2016 Feb; 169:13-20.
Score: 0.331
-
Forlenza GP, Sankaranarayanan S, Maahs DM. Refining the closed loop in the data age: research-to-practice transitions in diabetes technology. Diabetes Technol Ther. 2015 May; 17(5):304-6.
Score: 0.318
-
Bergenstal RM, Heller A, Breton MD, Vigersky R, Brown SA, Forlenza GP, Sherr JL, Hovorka R, Russell SJ, Damiano ER, Putman MS, Beck RW, Renard E, Lal R, Cobelli C, Dassau E, Akturk HK, Weiss MA, Skyler JS. Evolution of the Artificial Pancreas: Components and Integration-CGMs, Insulin, and AP Systems. J Diabetes Sci Technol. 2025 Jul; 19(4):883-894.
Score: 0.161
-
Berget C, Cobry E, Escobar E, Towers L, Sakomoto C, Taylor K, Trojanowski PJ, Wadwa RP, Forlenza GP. Sustained improvements in glycaemic and psychosocial outcomes for youth and caregivers using Omnipod 5 AID for 12?months. Diabetes Obes Metab. 2025 Sep; 27(9):4942-4949.
Score: 0.161
-
Leung HMC, Gong C, Geiser L, Fivekiller EE, Bui N, Vu T, Prioleau T, Forlenza GP, Liu Q, Zhou X. Clinical evaluation of a polarization-based optical noninvasive glucose sensing system. Sci Rep. 2025 Mar 14; 15(1):8877.
Score: 0.158
-
Waterman LA, Pyle L, Forlenza GP, Towers L, Karami AJ, Jost E, Berget C, Wadwa RP, Cobry EC. Accuracy of a Real-Time Continuous Glucose Monitor in Pediatric Diabetic Ketoacidosis Admissions. Diabetes Technol Ther. 2024 Sep; 26(9):626-632.
Score: 0.148
-
Forlenza GP, Dai Z, Niu F, Shin JJ. Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems. Diabetes Technol Ther. 2024 Mar; 26(S3):7-16.
Score: 0.147
-
Forlenza GP, DeSalvo DJ, Aleppo G, Wilmot EG, Berget C, Huyett LM, Hadjiyianni I, M?ndez JJ, Conroy LR, Ly TT, Sherr JL. Real-World Evidence of Omnipod? 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technol Ther. 2024 Aug; 26(8):514-525.
Score: 0.147
-
Leung HMC, Forlenza GP, Prioleau TO, Zhou X. Noninvasive Glucose Sensing In Vivo. Sensors (Basel). 2023 Aug 09; 23(16).
Score: 0.142
-
Cho S, Vigers T, Pyle L, Franklin A, Sopfe J, Jeney F, Forlenza G. Composite Metric of Glycemic Control Q-Score Is Elevated in Pediatric and Adolescent/Young Adult Hematopoietic Stem Cell Transplant Recipients. Diabetes Technol Ther. 2023 02; 25(2):116-121.
Score: 0.136
-
Galindo RJ, Aleppo G, Parkin CG, Baidal DA, Carlson AL, Cengiz E, Forlenza GP, Kruger DF, Levy C, McGill JB, Umpierrez GE. Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility Criteria. J Diabetes Sci Technol. 2024 Jul; 18(4):974-987.
Score: 0.135
-
Pauley ME, Tommerdahl KL, Snell-Bergeon JK, Forlenza GP. Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits. Curr Cardiol Rep. 2022 12; 24(12):2043-2056.
Score: 0.134
-
Forlenza GP, Carlson AL, Galindo RJ, Kruger DF, Levy CJ, McGill JB, Umpierrez G, Aleppo G. Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations. Diabetes Technol Ther. 2022 11; 24(11):814-823.
Score: 0.132
-
Forlenza GP, Ekhlaspour L, DiMeglio LA, Fox LA, Rodriguez H, Shulman DI, Kaiserman KB, Liljenquist DR, Shin J, Lee SW, Buckingham BA. Glycemic outcomes of children 2-6?years of age with type 1 diabetes during the pediatric MiniMed? 670G system trial. Pediatr Diabetes. 2022 05; 23(3):324-329.
Score: 0.127
-
Akturk HK, Vigers T, Forlenza G, Champakanath A, Pyle L. Comparison of Cgmanalysis, a Free Open-Source Continuous Glucose Monitoring Data Management and Analysis Software, with Commercially Available CGM Platforms: Data Standardization for Diabetes Technology Research. Diabetes Technol Ther. 2022 01; 24(1):54-60.
Score: 0.126
-
Forlenza GP, Vigers T, Berget C, Messer LH, Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM, Wadwa RP, Driscoll KA, Pyle L. Predicting Success with a First-Generation Hybrid Closed-Loop Artificial Pancreas System Among Children, Adolescents, and Young Adults with Type 1 Diabetes: A Model Development and Validation Study. Diabetes Technol Ther. 2022 03; 24(3):157-166.
Score: 0.126
-
Messer LH, Berget C, Pyle L, Vigers T, Cobry E, Driscoll KA, Forlenza GP. Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes. Diabetes Technol Ther. 2021 12; 23(12):837-843.
Score: 0.122
-
Berget C, Akturk HK, Messer LH, Vigers T, Pyle L, Snell-Bergeon J, Driscoll KA, Forlenza GP. Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use. Diabetes Obes Metab. 2021 09; 23(9):2048-2057.
Score: 0.122
-
Messer LH, Campbell K, Pyle L, Forlenza GP. Basal-IQ technology in the real world: satisfaction and reduction of diabetes burden in individuals with type 1 diabetes. Diabet Med. 2021 06; 38(6):e14381.
Score: 0.116
-
Cobry EC, Berget C, Messer LH, Forlenza GP. Review of the Omnipod? 5 Automated Glucose Control System Powered by Horizon? for the treatment of Type 1 diabetes. Ther Deliv. 2020 08; 11(8):507-519.
Score: 0.115
-
Shah VN, Forlenza GP. Suicide via Intentional Insulin Overdose Through First Commercial Hybrid Closed-Loop. J Diabetes Sci Technol. 2020 05; 14(3):687-688.
Score: 0.112
-
Sherr JL, Buckingham BA, Forlenza GP, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett LM, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technol Ther. 2020 03; 22(3):174-184.
Score: 0.109
-
Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, Shulman DI, Bailey TS, Bode BW, Wood MA, Buckingham BA, Kaiserman KB, Shin J, Huang S, Lee SW, Kaufman FR. Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes. Diabetes Technol Ther. 2019 01; 21(1):11-19.
Score: 0.103
-
Forlenza GP, Messer LH, Berget C, Wadwa RP, Driscoll KA. Biopsychosocial Factors Associated With Satisfaction and Sustained Use of Artificial Pancreas Technology and Its Components: a Call to the Technology Field. Curr Diab Rep. 2018 09 26; 18(11):114.
Score: 0.101
-
Forlenza GP, Cameron FM, Ly TT, Lam D, Howsmon DP, Baysal N, Kulina G, Messer L, Clinton P, Levister C, Patek SD, Levy CJ, Wadwa RP, Maahs DM, Bequette BW, Buckingham BA. Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance in Adolescents and Adults in a Supervised Hotel Setting. Diabetes Technol Ther. 2018 05; 20(5):335-343.
Score: 0.098
-
Buckingham BA, Forlenza GP, Pinsker JE, Christiansen MP, Wadwa RP, Schneider J, Peyser TA, Dassau E, Lee JB, O'Connor J, Layne JE, Ly TT. Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes Technol Ther. 2018 04; 20(4):257-262.
Score: 0.097
-
Breton MD, Cher?avvsky DR, Forlenza GP, DeBoer MD, Robic J, Wadwa RP, Messer LH, Kovatchev BP, Maahs DM. Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study. Diabetes Care. 2017 12; 40(12):1644-1650.
Score: 0.094
-
Howsmon DP, Cameron F, Baysal N, Ly TT, Forlenza GP, Maahs DM, Buckingham BA, Hahn J, Bequette BW. Continuous Glucose Monitoring Enables the Detection of Losses in Infusion Set Actuation (LISAs). Sensors (Basel). 2017 Jan 15; 17(1).
Score: 0.090
-
Jacobs PG, Levy CJ, Brown SA, Riddell MC, Cinar A, Boughton CK, Breton MD, Dassau E, Forlenza G, Henderson RJ, Hovorka R, Maahs DM, Munshi M, Murphy H, Polsky S, Pratley R, Putman MS, Shah VN, Wilson LM, Zisser H, Ekhlaspour L. Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems. J Diabetes Sci Technol. 2025 Jul; 19(4):937-949.
Score: 0.040
-
Jacobs PG, Levy CJ, Brown SA, Riddell MC, Cinar A, Boughton CK, Breton MD, Dassau E, Forlenza G, Henderson RJ, Hovorka R, Maahs DM, Munshi M, Murphy H, Polsky S, Pratley R, Putman MS, Shah VN, Wilson LM, Zisser H, Ekhlaspour L. Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems. Diabetes Technol Ther. 2025 Jul; 27(S3):S60-S71.
Score: 0.040
-
Berget C, Annan SF, Biester T, Choudhary P, Forlenza GP, Peters AL, Renard E, Deiss D. Practical considerations for using the Omnipod? 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe. Diabetes Obes Metab. 2025 Jun; 27(6):2909-2919.
Score: 0.040
-
DeSalvo DJ, Bode BW, Forlenza GP, Laffel LM, Buckingham BA, Criego AB, Schoelwer M, MacLeish SA, Sherr JL, Hansen DW, Ly TT. Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod? 5 Automated Insulin Delivery System. Diabetes Technol Ther. 2024 Jun; 26(6):383-393.
Score: 0.037
-
Shah VN, Kanapka LG, Akturk HK, Polsky S, Forlenza GP, Kollman C, Beck RW, Snell-Bergeon JK. Time in Range Is Associated with Incident Diabetic Retinopathy in Adults with Type 1 Diabetes: A Longitudinal Study. Diabetes Technol Ther. 2024 Apr; 26(4):246-251.
Score: 0.037
-
Cobry EC, Pyle L, Waterman LA, Forlenza GP, Towers L, Karami AJ, Jost E, Berget C, Wadwa RP. Accuracy of a Continuous Glucose Monitor During Pediatric Type 1 Diabetes Inpatient Admissions. Diabetes Technol Ther. 2024 Feb; 26(2):119-124.
Score: 0.037
-
Criego AB, Carlson AL, Brown SA, Forlenza GP, Bode BW, Levy CJ, Hansen DW, Hirsch IB, Bergenstal RM, Sherr JL, Mehta SN, Laffel LM, Shah VN, Bhargava A, Weinstock RS, MacLeish SA, DeSalvo DJ, Jones TC, Aleppo G, Buckingham BA, Ly TT. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2024 Jan; 26(1):11-23.
Score: 0.036
-
Pihoker C, Shulman DI, Forlenza GP, Kaiserman KB, Sherr JL, Thrasher JR, Buckingham BA, Kipnes MS, Bode BW, Carlson AL, Lee SW, Latif K, Liljenquist DR, Slover RH, Dai Z, Niu F, Shin J, Jonkers RAM, Roy A, Grosman B, Vella M, Cordero TL, McVean J, Rhinehart AS, Vigersky RA. Safety and Glycemic Outcomes During the MiniMedTM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes. Diabetes Technol Ther. 2023 11; 25(11):755-764.
Score: 0.036
-
Aleppo G, Hirsch IB, Parkin CG, McGill J, Galindo R, Kruger DF, Levy CJ, Forlenza GP, Umpierrez GE, Grunberger G, Bergenstal RM. Coverage for Continuous Glucose Monitoring for Individuals with Type 2 Diabetes Treated with Nonintensive Therapies: An Evidence-Based Approach to Policymaking. Diabetes Technol Ther. 2023 10; 25(10):741-751.
Score: 0.035
-
Cordero TL, Dai Z, Arrieta A, Niu F, Vella M, Shin J, Rhinehart AS, McVean J, Lee SW, Slover RH, Forlenza GP, Shulman DI, Pop-Busui R, Thrasher JR, Kipnes MS, Christiansen MP, Buckingham BA, Pihoker C, Sherr JL, Kaiserman KB, Vigersky RA. Glycemic Outcomes During Early Use of the MiniMed? 780G Advanced Hybrid Closed-Loop System with Guardian? 4 Sensor. Diabetes Technol Ther. 2023 09; 25(9):652-658.
Score: 0.035
-
Alonso GT, Triolo TM, Akturk HK, Pauley ME, Sobczak M, Forlenza GP, Sakamoto C, Pyle L, Frohnert BI. Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population. Diabetes Care. 2023 06 01; 46(6):1218-1222.
Score: 0.035
-
McVean J, Forlenza GP, Beck RW, Bauza C, Bailey R, Buckingham B, DiMeglio LA, Sherr JL, Clements M, Neyman A, Evans-Molina C, Sims EK, Messer LH, Ekhlaspour L, McDonough R, Van Name M, Rojas D, Beasley S, DuBose S, Kollman C, Moran A. Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2023 03 28; 329(12):980-989.
Score: 0.035
-
Wadwa RP, Reed ZW, Buckingham BA, DeBoer MD, Ekhlaspour L, Forlenza GP, Schoelwer M, Lum J, Kollman C, Beck RW, Breton MD. Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. N Engl J Med. 2023 03 16; 388(11):991-1001.
Score: 0.034
-
Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, Forlenza GP, Gallen G, Garg SK, Gershenoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, N?rgaard K, O'Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocr Rev. 2023 03 04; 44(2):254-280.
Score: 0.034
-
Garg SK, Grunberger G, Weinstock R, Lawson ML, Hirsch IB, DiMeglio LA, Pop-Busui R, Philis-Tsimikas A, Kipnes M, Liljenquist DR, Brazg RL, Kudva YC, Buckingham BA, McGill JB, Carlson AL, Criego AB, Christiansen MP, Kaiserman KB, Griffin KJ, Forlenza GP, Bode BW, Slover RH, Keiter A, Ling C, Marinos B, Cordero TL, Shin J, Lee SW, Rhinehart AS, Vigersky RA. Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial. Diabetes Technol Ther. 2023 01; 25(1):1-12.
Score: 0.034
-
Tauschmann M, Forlenza G, Hood K, Cardona-Hernandez R, Giani E, Hendrieckx C, DeSalvo DJ, Laffel LM, Saboo B, Wheeler BJ, Laptev DN, Yarhere I, DiMeglio LA. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring. Pediatr Diabetes. 2022 12; 23(8):1390-1405.
Score: 0.034
-
Messer LH, Buckingham BA, Cogen F, Daniels M, Forlenza G, Jafri RZ, Mauras N, Muir A, Wadwa RP, White PC, Russell SJ, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Marak MC, Calhoun P, Beck RW. Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial. Diabetes Technol Ther. 2022 10; 24(10):712-725.
Score: 0.033
-
Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Calhoun P, Wadwa RP, Buckingham B, Zhou K, Daniels M, Raskin P, White PC, Lynch J, Pettus J, Hirsch IB, Goland R, Buse JB, Kruger D, Mauras N, Muir A, McGill JB, Cogen F, Weissberg-Benchell J, Sherwood JS, Castellanos LE, Hillard MA, Tuffaha M, Putman MS, Sands MY, Forlenza G, Slover R, Messer LH, Cobry E, Shah VN, Polsky S, Lal R, Ekhlaspour L, Hughes MS, Basina M, Hatipoglu B, Olansky L, Bhangoo A, Forghani N, Kashmiri H, Sutton F, Choudhary A, Penn J, Jafri R, Rayas M, Escaname E, Kerr C, Favela-Prezas R, Boeder S, Trikudanathan S, Williams KM, Leibel N, Kirkman MS, Bergamo K, Klein KR, Dostou JM, Machineni S, Young LA, Diner JC, Bhan A, Jones JK, Benson M, Bird K, Englert K, Permuy J, Cossen K, Felner E, Salam M, Silverstein JM, Adamson S, Cedeno A, Meighan S, Dauber A. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 09 29; 387(13):1161-1172.
Score: 0.033
-
Polonsky WH, Hood KK, Levy CJ, MacLeish SA, Hirsch IB, Brown SA, Bode BW, Carlson AL, Shah VN, Weinstock RS, Bhargava A, Jones TC, Aleppo G, Mehta SN, Laffel LM, Forlenza GP, Sherr JL, Huyett LM, Vienneau TE, Ly TT. How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod? 5 System. Diabetes Res Clin Pract. 2022 Aug; 190:109998.
Score: 0.033
-
Ekhlaspour L, Raghinaru D, Forlenza GP, Isganaitis E, Kudva YC, Lam DW, Levister C, O'Malley G, Church MM, Lum JW, Buckingham B, Brown SA. Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop Trial. J Diabetes Sci Technol. 2023 Jul; 17(4):935-942.
Score: 0.032
-
Klonoff DC, Wang J, Rodbard D, Kohn MA, Li C, Liepmann D, Kerr D, Ahn D, Peters AL, Umpierrez GE, Seley JJ, Xu NY, Nguyen KT, Simonson G, Agus MSD, Al-Sofiani ME, Armaiz-Pena G, Bailey TS, Basu A, Battelino T, Bekele SY, Benhamou PY, Bequette BW, Blevins T, Breton MD, Castle JR, Chase JG, Chen KY, Choudhary P, Clements MA, Close KL, Cook CB, Danne T, Doyle FJ, Drincic A, Dungan KM, Edelman SV, Ejskjaer N, Espinoza JC, Fleming GA, Forlenza GP, Freckmann G, Galindo RJ, Gomez AM, Gutow HA, Heinemann L, Hirsch IB, Hoang TD, Hovorka R, Jendle JH, Ji L, Joshi SR, Joubert M, Koliwad SK, Lal RA, Lansang MC, Lee WA, Leelarathna L, Leiter LA, Lind M, Litchman ML, Mader JK, Mahoney KM, Mankovsky B, Masharani U, Mathioudakis NN, Mayorov A, Messler J, Miller JD, Mohan V, Nichols JH, N?rgaard K, O'Neal DN, Pasquel FJ, Philis-Tsimikas A, Pieber T, Phillip M, Polonsky WH, Pop-Busui R, Rayman G, Rhee EJ, Russell SJ, Shah VN, Sherr JL, Sode K, Spanakis EK, Wake DJ, Waki K, Wallia A, Weinberg ME, Wolpert H, Wright EE, Zilbermint M, Kovatchev B. A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. J Diabetes Sci Technol. 2023 09; 17(5):1226-1242.
Score: 0.032
-
Rosenfeld C, Blevins T, Aleppo G, Forlenza G, Isaacs D, Morales J, Seley J, Unger J. Expert Roundtable on Continuous Glucose Monitoring. Endocr Pract. 2022 Jun; 28(6):622-627.
Score: 0.032
-
Sawyer A, Sobczak M, Forlenza GP, Alonso GT. Glycemic Control in Relation to Technology Use in a Single-Center Cohort of Children with Type 1 Diabetes. Diabetes Technol Ther. 2022 06; 24(6):409-415.
Score: 0.032
-
O'Malley G, Messer LH, Levy CJ, Pinsker JE, Forlenza GP, Isganaitis E, Kudva YC, Ekhlaspour L, Raghinaru D, Lum J, Brown SA. Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial. Diabetes Technol Ther. 2021 04; 23(4):245-252.
Score: 0.030
-
Schoelwer MJ, Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cobry EC, Messer LH, Cengiz E, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, Buckingham BA, Lal RA, Oliveri MC, Kollman CC, Dokken BB, Cher?avvsky DR, Beck RW, DeBoer MD. Predictors of Time-in-Range (70-180?mg/dL) Achieved Using a Closed-Loop Control System. Diabetes Technol Ther. 2021 07; 23(7):475-481.
Score: 0.030
-
Alva S, Bailey T, Brazg R, Budiman ES, Castorino K, Christiansen MP, Forlenza G, Kipnes M, Liljenquist DR, Liu H. Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes. J Diabetes Sci Technol. 2022 Jan; 16(1):70-77.
Score: 0.029
-
Brown SA, Beck RW, Raghinaru D, Buckingham BA, Laffel LM, Wadwa RP, Kudva YC, Levy CJ, Pinsker JE, Dassau E, Doyle FJ, Ambler-Osborn L, Anderson SM, Church MM, Ekhlaspour L, Forlenza GP, Levister C, Simha V, Breton MD, Kollman C, Lum JW, Kovatchev BP. Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. Diabetes Care. 2020 08; 43(8):1822-1828.
Score: 0.028
-
Ravi SJ, Coakley A, Vigers T, Pyle L, Forlenza GP, Alonso T. Pediatric Medicaid Patients With Type 1 Diabetes Benefit From Continuous Glucose Monitor Technology. J Diabetes Sci Technol. 2021 05; 15(3):630-635.
Score: 0.028
-
Kovatchev B, Anderson SM, Raghinaru D, Kudva YC, Laffel LM, Levy C, Pinsker JE, Wadwa RP, Buckingham B, Doyle FJ, Brown SA, Church MM, Dadlani V, Dassau E, Ekhlaspour L, Forlenza GP, Isganaitis E, Lam DW, Lum J, Beck RW. Randomized Controlled Trial of Mobile Closed-Loop Control. Diabetes Care. 2020 03; 43(3):607-615.
Score: 0.028
-
Vigers T, Chan CL, Snell-Bergeon J, Bjornstad P, Zeitler PS, Forlenza G, Pyle L. cgmanalysis: An R package for descriptive analysis of continuous glucose monitor data. PLoS One. 2019; 14(10):e0216851.
Score: 0.027
-
Ekhlaspour L, Forlenza GP, Chernavvsky D, Maahs DM, Wadwa RP, Deboer MD, Messer LH, Town M, Pinnata J, Kruse G, Kovatchev BP, Buckingham BA, Breton MD. Closed loop control in adolescents and children during winter sports: Use of the Tandem Control-IQ AP system. Pediatr Diabetes. 2019 09; 20(6):759-768.
Score: 0.026
-
Anderson SM, Dassau E, Raghinaru D, Lum J, Brown SA, Pinsker JE, Church MM, Levy C, Lam D, Kudva YC, Buckingham B, Forlenza GP, Wadwa RP, Laffel L, Doyle FJ, DeVries JH, Renard E, Cobelli C, Boscari F, Del Favero S, Kovatchev BP. The International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability. Diabetes Technol Ther. 2019 02; 21(2):73-80.
Score: 0.026
-
Wood MA, Shulman DI, Forlenza GP, Bode BW, Pinhas-Hamiel O, Buckingham BA, Kaiserman KB, Liljenquist DR, Bailey TS, Shin J, Huang S, Chen X, Cordero TL, Lee SW, Kaufman FR. In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes. Diabetes Technol Ther. 2018 11; 20(11):731-737.
Score: 0.025
-
Sherr JL, Tauschmann M, Battelino T, de Bock M, Forlenza G, Roman R, Hood KK, Maahs DM. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies. Pediatr Diabetes. 2018 10; 19 Suppl 27:302-325.
Score: 0.025
-
Messer LH, Forlenza GP, Sherr JL, Wadwa RP, Buckingham BA, Weinzimer SA, Maahs DM, Slover RH. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System. Diabetes Care. 2018 04; 41(4):789-796.
Score: 0.024
-
Spaic T, Driscoll M, Raghinaru D, Buckingham BA, Wilson DM, Clinton P, Chase HP, Maahs DM, Forlenza GP, Jost E, Hramiak I, Paul T, Bequette BW, Cameron F, Beck RW, Kollman C, Lum JW, Ly TT. Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes. Diabetes Care. 2017 Mar; 40(3):359-366.
Score: 0.022
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|